Naibec Wins Order for Core Bio Materials at 'EAO 2024'... "Discussing Volume Expansion"

Naivek announced on the 4th that it successfully secured new orders for core bio-material products from global implant companies by participating in the European Association for Osseointegration (EAO).

The newly ordered items are collagen-centered products, with supply expected to begin in earnest early next year. With this order, the export items are diversified from existing bone regeneration materials to collagen products, accelerating the company's overseas market expansion.

The new client is a global company producing and selling a variety of product lines including tissue regeneration products, premium implant solutions, prosthetic solutions, and digital workflows. It has a solid sales network in over 90 countries worldwide, including North America, Europe, and Asia, and holds significant influence in the implant market by supporting various educational programs and clinical research for dental specialists.

At EAO, Naivek not only secured new orders for collagen products but also discussed expanding the supply of bone regeneration materials for next year with existing global partners such as Straumann and Nobel Biocare. As Naivek continuously expands approvals in new countries, it held order meetings with various global implant companies to broaden its global market presence.

During the event, Naivek actively promoted the excellence of its core bone regeneration bio-material products through a company forum it hosted, attracting significant attention from participants. Pascal Valentini, a global implant expert and former EAO president, delivered a presentation on clinical results of the products, highlighting their technological capabilities and superior quality.

Clinical representatives from Seoul National University and Frankfurt University in Germany, who conducted post-market clinical trials of Naivek’s core products ‘OCS-B’, ‘OCS-B Collagen’, and ‘Rizenomer’, also presented on the quality and efficacy of these clinical products. According to the company, Naivek’s flagship products, recognized by these experts, garnered considerable interest at this year’s EAO and led to new orders.

A Naivek official stated, “Sales of bone regeneration material products are steadily increasing in our main market, Europe, and sales are gradually rising in the U.S. and China as well, so we expect favorable performance in the second half of the year. Next year, not only is an increase in supply volume of bone regeneration materials to existing global partners anticipated, but the addition of newly ordered collagen-centered products is expected to drive significant sales growth.”

He added, “With the acquisition of European medical device (CE MDR) certification, we will expand export countries within Europe and actively grow overseas markets through additional individual export approvals in countries such as Brazil, Russia, and Japan. We will continue performance growth by diversifying our portfolio with new products like the tissue regeneration inducer ‘Pepticol EasyGraft’ series.”

EAO is a global academic organization established to promote research, education, and clinical trials in the fields of dental implants and oral reconstruction. EAO serves as a platform for dental professionals worldwide to share the latest research and clinical experiences in related fields. This year, the event was held in Milan, Italy, from the 24th to the 26th of last month, with participation from 4,700 dental professionals worldwide.

This content was produced with the assistance of AI translation services.